{"disease":{"id":"beta-thalassemia-intermedia","name":"beta thalassemia intermedia"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT06831799","title":"ERN-EuroBloodNet Registry on Patients With Rare Red Blood Cell Defects and COVID-19","phase":"","overall_status":"COMPLETED","enrollment_count":684,"lead_sponsor_name":"Hospital Universitari Vall d'Hebron Research Institute","has_results":false},{"nct_id":"NCT01571635","title":"Study to Determine the Safety and Tolerability of Sotatercept (ACE-011) in Adults With Beta( β)- Thalassemia.","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":46,"lead_sponsor_name":"Celgene","has_results":true},{"nct_id":"NCT04432623","title":"The BENeFiTS Trial in Beta Thalassemia Intermedia","phase":"PHASE1, PHASE2","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":36,"lead_sponsor_name":"Phoenicia BioScience","has_results":false},{"nct_id":"NCT04059406","title":"Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Sapablursen (Formerly ISIS 702843, IONIS-TMPRSS6-LRx)","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":29,"lead_sponsor_name":"Ionis Pharmaceuticals, Inc.","has_results":true}],"total":4},"guidelines":[],"source":"Drug Landscape verified database"}